ZNF350: A Potential Drug Target for Various Diseases (G59348)
ZNF350: A Potential Drug Target for Various Diseases
ZNF350 (ZBRK1), a protein encoded by the Zinc Finger Nucleosome 350 gene, is a key regulator of chromatin structure and function. It plays a vital role in the maintenance of genomic stability, and is highly expressed in various tissues, including brain, muscle, and epithelial cells. ZNF350 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, it has become an attractive drug target for researchers to explore new therapeutic approaches.
The ZNF350 gene is located on chromosome 16, and encodes a protein of 21 kDa. ZNF350 is composed of a nucleosome core, a C-terminal region that includes a Zinc Finger domain, and a C-terminal region that includes a nucleotide-binding oligomerization domain (NBO domain). The ZNF350 protein functions as a nucleosome protein, which is responsible for the organization and stability of chromatin.
ZNF350 is highly expressed in various tissues, including brain, muscle, and epithelial cells. It is expressed at levels of up to 10% of total gene expression in muscle cells and up to 5% in brain cells. ZNF350 is also highly expressed in various cancer types, including breast, ovarian, and colorectal cancer. This suggests that targeting ZNF350 may be an effective way to treat certain types of cancer.
In addition to its expression in cancer cells, ZNF350 is also involved in the development and progression of neurodegenerative diseases. It has been shown to be involved in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. ZNF350 has also been implicated in the development of certain psychiatric disorders, such as major depressive disorder and schizophrenia. These findings suggest that targeting ZNF350 may be a valuable approach to treating neurodegenerative diseases.
ZNF350 has also been shown to be involved in the regulation of cellular processes that are important for human health and development. It plays a role in the development and maintenance of the nervous system, and is involved in the regulation of neurotransmitter signaling and cell signaling pathways. ZNF350 has also been shown to be involved in the regulation of cell growth and differentiation, and is involved in the development and maintenance of tissues such as the brain and nervous system.
Given the involvement of ZNF350 in so many different cellular processes that are important for human health and development, it is not surprising that it has become an attractive drug target for researchers. Many studies have investigated the effects of drugs that interact with ZNF350, in order to determine if these drugs can be effective in treating various diseases. Some of the drugs that have been shown to interact with ZNF350 include:
1. Tetrandron: Tetrandron is a drug that is being investigated for the treatment of various cancers, including breast, ovarian, and colorectal cancer. Tetrandron is shown to interact with ZNF350, and may inhibit the activity of this protein.
2. N-Acetylcysteine (NAC): NAC is a drug that is being investigated for the treatment of various neurological disorders, including Alzheimer's disease and Parkinson's disease. NAC is shown to interact with ZNF350, and may inhibit the activity of this protein.
3. Ursodeoxycholic acid (UDCA): UDCA is a drug that is being investigated for the treatment of various gastrointestinal disorders, including Inflammatory Bowel Disease (IBD) and Non-Alcoholic Steatohepatitis (NASH). UDCA is shown to interact with ZNF350, and may inhibit the activity of this protein.
In conclusion, ZNF350 is a protein that is highly expressed in various tissues and is involved in
Protein Name: Zinc Finger Protein 350
Functions: Transcriptional repressor. Binds to a specific sequence, 5'-GGGxxxCAGxxxTTT-3', within GADD45 intron 3
The "ZNF350 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF350 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2
